Choroidal Osteoma

A choroidal osteoma is an unusual, non‑cancerous growth made of true, mature bone that forms inside the choroid—the vascular, brown‑red layer lying between the retina and the white sclera of the eye. Instead of spongy blood‑rich tissue, a patch of the choroid gradually hardens into cancellous bone. Doctors first recognised the condition in the mid‑1970s, and since then fewer than a few hundred cases have appeared in the world literature. Although the lesion itself is benign, it can disturb vision by thinning the overlying retinal pigment epithelium (RPE), by triggering serous retinal detachments, or—most commonly—by seeding a choroidal‑neovascular membrane (CNV) that leaks and scars the central retina. EyeWikiPMC

Scientists still debate the root cause. Some view the tumour as an osseous choristoma—in other words, normal bone tissue that simply pops up in the wrong place. Others suspect chronic low‑grade inflammation, subtle developmental errors, hormonal influences (explaining its preference for teenage and young‑adult women), trauma, or disordered local calcium regulation. None of these theories has been proved, and blood calcium, phosphate, and alkaline‑phosphatase levels are usually normal. Current thinking is that multipotent stromal cells in the choroid transform into osteoblast‑like cells under an unknown molecular cue; they then lay down lamellar bone, complete with marrow‑like spaces and tiny feeding vessels. Over years the slab may decalcify from the edges inward; paradoxically, that shrinking bone can provoke new vessels that burrow through breaks in Bruch’s membrane, producing the sight‑threatening CNV. EyeWikiPMC

---

Types of choroidal osteoma

Doctors do not use a single rigid classification, but three descriptive groupings help in the clinic:

• Classic (fully‑calcified) lesions. These appear yellow‑white to orange‑red, have crisp scalloped borders, and cast an acoustic shadow on ultrasound. Vision may be normal until complications arise.

• Partially decalcified lesions. Grey‑yellow patches mark areas where mineral has leached away. The overlying RPE becomes thin, so photoreceptors lose metabolic support and visual sensitivity drops. CNV risk rises here.

• Fully decalcified remnants. Eventually only a faint pale scar remains. The tumour is biologically quiet, but whatever retinal damage occurred during the decalcification phase is permanent.

Another practical scheme divides osteomas by location (juxtapapillary, peripapillary, macular, or mixed) and by laterality (about 80 % are unilateral; 20 % involve both eyes, sometimes years apart). While none of these “types” alters the benign nature of the bone itself, they predict what part of the visual field will suffer first and guide follow‑up imaging schedules. EyeWiki

---

Causes

Remember, no single cause has been proved; each item below reflects associations reported in small case series or experimental work.

1. Congenital choristoma theory. Some babies are born with minute foci of ectopic bone in the choroid that enlarge later in life. The congenital hypothesis fits sporadic paediatric reports, yet it fails to explain adult‑onset lesions that suddenly grow after decades of apparent quiescence. PMC

2. Genetic susceptibility. Very rare familial clusters hint that certain yet‑unknown genes may prime choroidal cells toward ossification when exposed to environmental triggers.

3. Chronic intra‑ocular inflammation. Recurrent uveitis or posterior scleritis bathes the choroid in cytokines such as interleukin‑6. Animal work suggests these signals can coax stromal fibroblasts to express bone matrix proteins.

4. Previous ocular trauma or surgery. Mechanical injury may fracture Bruch’s membrane, release bone morphogenetic proteins (BMPs), and seed osteogenesis.

5. Hormonal milieu of the teenage years. Oestrogen and growth hormone surge precisely when most cases first appear; both hormones modulate osteoblast activity systemically, so a parallel effect inside the eye is plausible.

6. Abnormal local calcium metabolism. Even with normal blood tests, micro‑environmental calcium phosphate supersaturation inside the choroid could nucleate apatite crystals that scaffold bone formation.

7. Systemic bone or mineral disorders. Conditions like Paget’s disease or hyperparathyroidism have been reported in isolated patients, though a direct mechanistic link is missing.

8. Vascular malformations of the choroid. Tangled choroidal vessels may generate turbulent flow and peri‑vascular hypoxaemia, nudging mesenchymal cells toward an osteogenic lineage.

9. High‑altitude oxidative stress. One case series from Andean populations proposed chronic hypoxia as a co‑factor, but numbers were too small for firm conclusions.

10. Environmental toxins. Chronic exposure to heavy metals (lead, cadmium) alters calcification pathways elsewhere in the body; whether they reach sufficient intra‑ocular levels is unclear.

11. Auto‑immune connective‑tissue disease. Lupus or sarcoidosis occasionally coincide with osteomas, perhaps through shared inflammatory mediators.

12. Posterior scleritis‑related ossification. Long‑standing posterior scleral inflammation has directly preceded osteoma formation in scattered patients. Lippincott Journals

13. Endocrine influences of pregnancy. Fluctuating progesterone and placental growth factors have twice been linked to a sudden growth spurt of a previously silent lesion.

14. Chorioretinal infections. Scars from old toxoplasmosis or tuberculosis alter Bruch’s membrane integrity; speculative reports suggest they can seed osteoid, although definite proof is lacking.

15. Idiopathic ossification. In many otherwise healthy individuals none of the above apply. The lesion may simply represent a sporadic error in ocular tissue programming.

---

Common symptoms

1. Blurred central vision. As bone expands under the macula, the overlying photoreceptors cannot focus light sharply, so reading and recognising faces become hazy.

2. Metamorphopsia (wavy lines). When the retina drapes unevenly over the bony plateau, straight objects bend or ripple, a classic complaint on the Amsler grid.

3. Scotoma (blind spot). A well‑circumscribed patch of bone can block or distort light, creating a missing piece in the visual scene that patients notice when searching for print on a page.

4. Colour desaturation. The macula’s cone cells are most sensitive to colour; when chronic oedema or RPE loss sets in, reds look dull and blues washed out.

5. Photopsia (flashes of light). Microscopic traction between decalcifying bone and retina can fire errant electrical signals that patients interpret as sparkle or lightning streaks.

6. Floaters and hazy shadows. Leakage from a CNV may spill blood or lipids into the vitreous cavity, adding new spots that drift across the field of view.

7. Difficulty in dim light. Rod cells rely on healthy RPE recycling; once that support thins, night driving or theatre lighting becomes challenging long before daytime vision falls.

8. Contrast‑loss in bright sunlight. Light scatter off irregular bone edges and chronic macular oedema both rob the eye of crisp edges, especially against high‑glare backgrounds.

9. Peripheral field defect. Juxtapapillary growth can crowd the optic‑nerve head or compress adjacent nerve‑fibre bundles, trimming side vision.

10. Painless but progressive decline. Unlike inflammatory eye diseases, osteoma causes little redness or ache; its silent but relentless advance often delays diagnosis until vision has already slipped. EyeWiki

---

Diagnostic tests

Physical‑exam–based tests

Visual‑acuity chart testing. Simple Snellen or ETDRS lines quantify how many high‑contrast letters a person can discern. A falling acuity may flag macular encroachment long before ophthalmoscopy alone can track subtle tumour creep.

Pupillary light‑reflex assessment. A swinging‑flashlight test checks for a relative afferent pupillary defect; although rare, a large osteoma stressing the optic nerve can create an asymmetric response.

Confrontational visual‑field probing. Wiggling fingers in each quadrant quickly screens for blind spots caused by peripapillary or large eccentric lesions.

Direct ophthalmoscopy / slit‑lamp biomicroscopy. Through a dilated pupil the doctor sees a plateau‑like, yellow‑white mass with geographic edges, as well as grey‑green CNV or peppery RPE depigmentation. EyeWiki

Manual chair‑side tests

Amsler grid. The patient stares at a central dot on a square grid; any bending, warping, or missing boxes localises functional loss over the osteoma.

Photostress recovery time. After bleaching the macula with bright light, the clinician measures how long vision takes to return; prolonged recovery hints at dysfunction in the RPE‑photoreceptor complex above the tumour.

Colour‑vision plates (Ishihara or Farnsworth). Fading or mis‑reading colour patterns provides a sensitive though non‑specific clue to macular compromise.

Laboratory and pathological tests

Serum calcium‑phosphate profile. Most patients show normal values, yet checking excludes metabolic bone diseases that can imitate or exacerbate ocular ossification.

Parathyroid‑hormone assay. Hyper‑ or hypo‑parathyroidism can skew calcium homeostasis; a normal result supports the “local, not systemic” nature of the lesion.

Inflammatory markers (ESR/CRP). When posterior scleritis or systemic vasculitis is suspected, a raised level signals active inflammation needing separate treatment.

Electrodiagnostic tests

Full‑field electroretinogram (ERG). Measures the summed electrical response of rods and cones. A depressed macular component but preserved peripheral waveform suggests central retinal stress overlying the bony plate.

Electro‑oculogram (EOG). Assesses RPE pump function; a low Arden ratio correlates with widespread RPE atrophy that sometimes surrounds decalcifying osteoma margins.

Visual‑evoked potential (VEP). Delayed P100 latencies can appear if optic‑nerve fibres suffer from chronic oedema or if a large juxtapapillary lesion disrupts signal flow.

 Imaging tests

Fundus photography. Serial colour photos capture changes in tumour size, pigment mottling, and haemorrhage from new vessels; they form the baseline for all follow‑up.

Spectral‑domain optical coherence tomography (SD‑OCT). This high‑resolution “optical biopsy” shows dense hyper‑reflectivity of calcified bone, overlying photoreceptor loss, and any sub‑retinal fluid pocket.

Swept‑source OCT (SS‑OCT). Longer‑wavelength beams penetrate bone better, revealing internal lamellae, choriocapillaris loss, or optically empty caverns inside decalcified zones—features now linked to a higher risk of CNV. PMC

B‑scan ultrasonography. The bone’s high acoustic reflectivity produces a bright echo with posterior shadowing; ultrasound also rules out mimics such as amelanotic melanoma or sclerochoroidal calcification.

Fundus fluorescein angiography (FFA). Hyper‑fluorescent hot spots pinpoint leaking CNV, while blocked fluorescence maps dense calcified cores.

Indocyanine‑green angiography (ICGA). Penetrates pigment and fluid better than fluorescein, highlighting deeper choroidal feeder vessels or polypoidal outpouchings that can complicate osteoma.

Orbital computed tomography (CT). Thin‑slice CT shows a discrete, plaque‑like ossification with bone density (high Hounsfield units) hugging the globe, confirming the lesion in equivocal cases. MRI is less useful because cortical bone gives poor signal. EyeWiki

Non‑Pharmacological Treatments

Below are evidence‑supported, doctor‑approved lifestyle and rehabilitation tools. They are grouped into Exercise Therapies, Mind‑Body Practices, and Educational Self‑Management. Each paragraph explains what it is, why it helps, and how it works.

1. Saccadic‑tracking drills teach the eyes to jump precisely between letters, improving reading speed when central vision is patchy. Daily 10‑minute practice redirects fixation to healthier retinal zones.

2. Smooth‑pursuit exercises (following a slow‑moving target) strengthen ocular motor control, easing visual fatigue.

3. Contrast‑click training uses high‑contrast charts that fade over weeks, pushing neural circuits to detect faint signals and compensate for low contrast caused by osteoma shadows.

4. Peripheral‑awareness walking – guided ambulation with a low‑vision therapist expands visual field scanning, lowering fall risk.

5. Hand–eye coordination games (larger-print puzzles or ball toss) reinforce depth cues that decalcification can disturb.

6. Near‑vision endurance sets (20‑20‑20 rule with magnifiers) prevent accommodative strain.

7. Adaptive reading posture coaching teaches head tilt and lamp positioning to bypass scotomas.

8. Mindfulness meditation calms anxiety that often spikes after sudden vision loss; reduced cortisol may also protect micro‑circulation.

9. Guided imagery for pain and glare helps patients imagine “cooling light” to lessen photophobia episodes.

10. Progressive muscle relaxation lowers systemic blood pressure fluctuations that can trigger CNV leakage.

11. Yoga focusing on drishti (gaze points) stabilizes fixation and boosts ocular blood flow through slow diaphragmatic breathing.

12. Tai Chi combines balance and gentle eye tracking, improving both postural stability and retinal perfusion.

13. Box‑breathing (4‑4‑4‑4 pattern) enhances parasympathetic tone, indirectly supporting retinal autoregulation.

14. Low‑vision education classes teach lens choices, magnifiers, and smartphone accessibility tools, raising independence scores.American Osteopathic Association

15. Assistive‑tech training (screen readers, text‑to‑speech) bridges reading gaps, reducing cognitive load.

16. Daily‑living skills coaching shows safer kitchen layouts and high‑contrast labeling, preventing household injuries.

17. Peer‑support groups share coping hacks, lowering depression rates common in sight‑threatening disease.

18. Stress‑management workshops teach CBT techniques that reduce sympathetic surges and VEGF expression.

19. Nutrition counselling guides carotenoid‑rich diet choices (see supplements section) to shore up retinal antioxidant defenses.

20. Smoking‑cessation programs – quitting lowers oxidative stress and slows CNV recurrence.

---

Evidence‑Based Drugs Used in Practice

Note: Always follow your ophthalmologist’s exact protocol.

1. Ranibizumab 0.5 mg intravitreal injection (Anti‑VEGF class) every 4 weeks for active CNV; common side effects: transient floaters, rare endophthalmitis.PubMed

2. Bevacizumab 1.25 mg intravitreal off‑label; similar schedule and class; lower cost but equal efficacy.

3. Aflibercept 2 mg intravitreal every 8 weeks after loading; traps VEGF‑A/B and placental growth factor, useful in aggressive lesions.

4. Verteporfin 6 mg / m² IV with photodynamic therapy (PDT) once, repeat at 3‑month intervals if leakage persists; side effects: infusion‑site pain, temporary photosensitivity.PubMed

5. Triamcinolone acetonide 4 mg intravitreal for refractory fluid; class: corticosteroid; risks cataract and IOP rise.

6. Alendronate 70 mg orally weekly (bisphosphonate) investigated for inhibiting osteoclastic activity within the tumor; side effects: heartburn, rare jaw osteonecrosis.ScienceDirect

7. Zoledronic acid 5 mg IV yearly (bisphosphonate) in rapidly enlarging bilateral osteoma; flu‑like reaction possible.

8. Calcitonin 200 IU intranasal daily – theoretical calcium rebalancing; minor nasal irritation.

9. Doxycycline 100 mg orally twice daily for four weeks; matrix‑metalloproteinase inhibitor that may stabilize CNV; causes sun sensitivity.

10. Valproic acid 500 mg orally twice daily under study for neuro‑protective gene modulation; watch for liver enzyme elevation.

---

Dietary Molecular Supplements

1. Lutein 10 mg + Zeaxanthin 2 mg daily – accumulate in macular pigment, filtering blue light and quenching free radicals.

2. Omega‑3 fatty acids (DHA/EPA) 1,000 mg daily – anti‑inflammatory, improve retinal blood flow.

3. Vitamin A 5,000 IU daily – supports photoreceptor outer‑segment renewal; excess can be toxic, so stay within RDA.

4. Vitamin C 500 mg daily – regenerates oxidized vitamin E and stabilizes collagen in Bruch’s membrane.

5. Vitamin E 400 IU mixed‑tocopherols – lipid‑phase antioxidant guarding photoreceptor membranes.

6. Zinc 25 mg elemental daily – cofactor in retinal metabolism and superoxide dismutase activity.

7. Copper 2 mg daily – balances zinc therapy, preventing deficiency anemia.

8. Beta‑carotene 15 mg daily – provitamin A carotenoid; avoid in smokers due to lung cancer risk.

9. Resveratrol 150 mg daily – polyphenol that down‑regulates VEGF gene expression in lab models.

10. Astaxanthin 6 mg daily – potent marine carotenoid that crosses the blood‑retina barrier, combating oxidative damage.

---

Regenerative or Stem‑Cell‑Based Therapies Under Investigation

1. iPSC‑Derived RPE Patch (single sub‑retinal sheet) – patient’s own skin cells re‑programmed and placed under the macula; function: replace diseased RPE, mechanism: restore metabolic support to photoreceptors.TIME

2. Human embryonic stem‑cell RPE injection (50,000 cells, single surgery) – early trials show vision gain with no tumor formation for up to 37 months.The Guardian

3. Mesenchymal stem‑cell–derived exosome eye drops (twice daily in trials) – tiny vesicles deliver growth factors that quiet inflammation and promote vascular stability.PMC

4. rAAV2‑sFLT01 gene therapy (sub‑retinal bolus) – delivers a soluble VEGF receptor protein, offering “built‑in” anti‑VEGF expression.

5. Lenadogene nparvovec (intravitreal) – uses an AAV2/2 vector to supply ND4 gene analog, aiming at mitochondrial support in high‑energy macular cells.

6. RGX‑314 (suprachoroidal injection) – AAV8 coding for anti‑VEGF fab fragment; early data show reduced need for injections.

Dosages above refer to the procedural dose because these are one‑time or infrequent interventions done in surgical suites.

---

Surgical or Procedural Options

1. Photodynamic Therapy (PDT) – Out‑patient IV verteporfin plus cold laser activates local free‑radicals that seal leaking CNVM without burning the retina. Benefits: preserves tissue architecture and can shrink tumor edge.PubMed

2. Pars‑plana vitrectomy with decalcification – Surgeon cores out the calcific block through a small choroidotomy, relieving sub‑retinal stress; benefits: may stop rapid growth, but carries retinal detachment risk.PubMed

3. Macular translocation surgery – Rotates the retina to healthier choroid, bypassing the osteoma; benefit: re‑positions fovea away from scar.

4. Focal laser photocoagulation – Gold‑standard for extrafoveal CNVM; cauterizes leak points, preventing hemorrhage.

5. Plaque brachytherapy (custom radio‑isotope disc) – Reserved for aggressive lesions with secondary CNVM unresponsive to injections; shrinks vascular complex with localized radiation.

---

Practical Prevention Tips

1. Schedule yearly dilated eye exams for early CNV detection.

2. Protect eyes from intense sunlight with UV‑blocking wrap‑around glasses.

3. Maintain a carotenoid‑rich diet (leafy greens, orange peppers).

4. Stop smoking—tobacco quadruples oxidative stress in retinal tissue.

5. Manage blood‑pressure and cholesterol to keep choroidal flow steady.

6. Use safety goggles during sports or DIY projects to avoid trauma‑triggered bleeds.

7. Control systemic inflammatory diseases (e.g., lupus) under a physician’s care.

8. Treat osteoporosis early; bone metabolism modulators may influence tumor calcification.

9. Monitor hormonal therapies; discuss estrogen dose adjustments with your doctor.

10. Track new visual symptoms immediately in a vision diary for prompt intervention.

---

When Should You See an Eye Doctor Urgently?

Seek same‑week care if you notice a sudden gray shadow, straight lines bending, fresh floaters, flashing lights, or any drop in central vision. Rapid anti‑VEGF treatment within days greatly improves the odds of vision recovery.PubMed

---

Things to Do—and Ten to Avoid

Do:

1. Follow injection schedules precisely.

2. Use prescribed magnifiers and good task lighting.

3. Take antioxidant supplements after medical clearance.

4. Keep blood sugar and pressure controlled.

5. Adopt the 20‑20‑20 eye‑rest rule.
   Avoid:

6. Skipping follow‑up visits.

7. Smoking or second‑hand smoke exposure.

8. High‑impact sports without eye protection.

9. Unverified internet “miracle cures.”

10. Excessive alcohol, which depletes retinal vitamin A stores.

---

Frequently Asked Questions (FAQs)

1. Is choroidal osteoma cancer?
    No—it is benign bone, not malignant tissue.

2. Can it spread to the other eye?
    Rarely; most patients remain unilateral, but bilateral cases exist.

3. Will the tumor keep growing forever?
    Growth often plateaus after a few years; your doctor tracks size with ultrasound or OCT.

4. Does decalcification mean it’s getting better?
    Not necessarily—while bone thins, the overlying retina may atrophy, lowering vision.

5. Are injections painful?
    Numbing drops and lidocaine make the sting minimal; the whole process takes minutes.

6. How long do I need injections?
    Some need only three; others enter a “treat‑and‑extend” plan for years.

7. Is PDT safer than laser?
    For macular lesions, yes—PDT spares photoreceptors because it acts only where verteporfin is present.

8. Will supplements cure me?
    They support retinal health but cannot dissolve bone; think of them as eye multivitamins.

9. Can I still drive?
    If one eye maintains 20/40 vision and good field, many regions permit driving; check local laws.

10. Is pregnancy risky?
     Hormonal surges might fuel growth; schedule extra eye checks if you become pregnant.

11. Could gene therapy replace injections?
     Several trials show promise, but FDA approval is still pending.

12. What is my long‑term outlook?
     About half of patients keep functional vision for decades, especially with early CNV control.JAMA Network

13. Does screen time worsen it?
     Blue‑light strain is minor compared to other factors; use night‑mode and blink often.

14. Can children get it?
     Yes, but extremely rarely; pediatric cases follow similar principles.

15. Is there a support group?
     Low‑vision associations and online forums provide community and practical tips.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: July 16, 2025.

PDF Document For This Disease Conditions References